MEF2D

Across TCGA pan-cancer cohorts, MEF2D mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MEF2D’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MEF2D mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MEF2D is over-expressed in tumor, although a few such as LSCC and OV show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where MEF2D tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MEF2D mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.319	<.001	11	view →
PDAC	All	II,III,IV	+0.328	<.001	7	view →
LSCC	Male	III,IV	−0.256	<.001	6	view →
OV	All	All	−0.475	.009	2	view →
HNSC	All	IV	+0.153	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MEF2D–CCRCC

Open the CCRCC breakdown →